Inam Ullah

Inam Ullah
  • PhD Cardiology
  • PhD Student at Nanjing Medical University

PhD Cardiology. Looking for potential collaboration in terms of publications.

About

18
Publications
1,227
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
71
Citations
Introduction
Inam Ullah currently works at the Department of Cardiology, Nanjing Medical University, P.R. China. Inam's research interests include coronary heart disease, myocardial infarction, antiplatelet drugs, chronic total occlusion, radial access interventions, and anticoagulant drugs.
Current institution
Nanjing Medical University
Current position
  • PhD Student
Additional affiliations
September 2019 - present
Nanjing Medical University
Position
  • MS
Education
September 2014 - August 2017
Khyber Medical University
Field of study
  • BS (Cardiology)

Publications

Publications (18)
Article
Full-text available
Objective: In patients with coronary artery disease, dual antiplatelet therapy (DAPT) is recommended after percutaneous coronaryintervention, but the duration is still debated. This meta-analysis compared short-duration (1 to 3 months) to standard-time (twelve months) double antiplatelet treatment in patients who received coronary intervention with...
Article
Full-text available
It is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end-stage renal disease (ESRD). 86 CAD patients complicated with ESRD requiring hemodialysis were consecutive...
Article
Full-text available
Aims Data about whether empirical superior vena cava (SVC) isolation (SVCI) improves the success rate of paroxysmal atrial fibrillation (PAF) are conflicting. This study sought to first investigate the characteristics of SVC-triggered atrial fibrillation and secondly investigate the impact of electroanatomical mapping–guided SVCI, in addition to ci...
Article
Full-text available
Background Animal studies demonstrated that deeper lesions could be achieved during radio-frequency catheter ablation (RFCA) by using half saline (HS) compared to normal saline (NS) as irrigation. Objectives This study sought to compare the efficiency and safety of HS and NS for irrigation during RFCA of idiopathic outflow tract ventricular arrhyt...
Preprint
Full-text available
Background It is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end‑stage renal disease (ESRD). Methods 86 CAD patients complicated with ESRD requiring hemodialys...
Research
Full-text available
Background: Hyperthyroidism causes a rise in cardiovascular disease and dysrhythmias, leading to increased mortality. Low serum thyrotropin levels are a known independent risk factor for atrial fibrillation (AF). The frequency of hyperthyroidism in patients with AF is still unknown. Objectives: To determine the prevalence of hyperthyroidism in pati...
Preprint
Full-text available
Background Percutaneous coronary intervention (PCI) of coronary chronic total occlusion (CTO) is one of the most challenging procedures of interventional cardiology. Debate continues with regard to the predictors that influence the antegrade procedure outcome. Methods The CTO PCIs were prospectively registered from May 1, 2012 to August 22, 2017 i...
Article
Doxorubicin (DOX), a clinical chemotherapeutic drug, is often annoyed by its cardiotoxicity which involves ferroptosis in its pathological progress. Human umbilical cord mesenchymal stem cells (HucMSCs)-derived exosomes (HucMSCs-Exo) are proven effective in treating cardiovascular diseases. This study aimed to compare the therapeutic effects betwee...
Article
Full-text available
Background: Previous studies have suggested that proton pump inhibitors could impair the antiplatelet effect of clopidogrel. It is uncertain whether ilaprazole affects the antiplatelet effect of clopidogrel. This study aimed to determine the drug-drug interaction between ilaprazole and clopidogrel. Methods: A randomized crossover trial of 40 health...
Article
Full-text available
Background Insulin receptor substrate‐1 ( IRS‐1 ) rs956115 is associated with vascular risk in patients with coronary artery disease and concomitant diabetes. CYP2C19*2 (rs4244285) modulates clopidogrel response and predicts the outcome of coronary artery disease. This study was designed to explore the association between IRS‐1 , CYP2C19*2 genotype...
Article
Full-text available
PurposeThis study aimed to investigate the pharmacodynamic effects of indobufen and low-dose aspirin in patients with coronary atherosclerosis.Methods In the first phase, 218 patients with coronary atherosclerosis were randomly assigned to receive aspirin 100 mg once daily (standard dose); 100 mg once every 2 days; 100 mg once every 3 days; 50 mg t...
Preprint
Full-text available
Background insulin receptor substrate-1 (IRS-1) rs956115 is associated with vascular risk in patients with coronary artery disease (CAD) and concomitant diabetes. CYP2C19 rs4244285 modulates clopidogrel responsiveness and predicts outcome of CAD. We designed this study to explore the association between IRS-1 rs956115, CYP2C19 rs4244285, and platel...
Article
Full-text available
Objective This study was aimed to determine how platelet reactivity (PR) on dual antiplatelet therapy predicts ischemic and bleeding events in patients underwent percutaneous coronary intervention (PCI). Design A total of 2768 patients who had received coronary stent implantation and had taken aspirin 100 mg in combination with clopidogrel 75 mg d...
Article
Full-text available
High on‐treatment platelet reactivity (HOPR) is associated with increased risk of cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). We randomised post‐PCI patients with HOPR after 5 days of standard dual antiplatelet therapy (DAPT) to intensified therapy with aspirin 100 mg once daily in combination with either...
Preprint
Full-text available
Objective This study was aimed to investigate an optimal therapeutic window for platelet reactivity (PR) to predict the lowest ischemic and bleeding events in patients underwent percutaneous coronary intervention (PCI) and treated with dual antiplatelet agents. Design A total of 1709 patients who had received coronary stent implantation and had tak...
Research
Full-text available
Risk factors for ventricular tachycardia in acute ST-elevated myocardial infarction patients of a tertiary care hospital of Peshawar.
Article
Full-text available
Introduction: Ventricular arrhythmias are the most common cause of death in various ST-Elevated Myocardial Infarction (STEMI) patients and can be prevented if diagnosed and managed in time. Objectives: To document the occurrence of ventricular tachycardia in patients with acute ST-segment elevated myocardial infarction (STEMI) admitted to a tertiar...

Network

Cited By